atezolizumab + niraparib

Atezolizumab + niraparib is a **combination of two anti-cancer drugs**: atezolizumab, a monoclonal antibody targeting the immune checkpoint programmed death-ligand 1 (PD-L1), and niraparib, a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes PARP1 and PARP2. This combination is being studied mainly for the treatment of **recurrent ovarian cancer**, particularly as part of maintenance therapy following chemotherapy. The rationale stems from combining immunotherapy effects—by reactivating anti-tumor immunity and blocking immune evasion via PD-L1 inhibition—with targeted DNA repair defects in tumor cells through PARP inhibition, which increases cell death in homologous recombination-deficient cancer cells. While the combination has been tested in phase III studies, addition of atezolizumab to chemotherapy and maintenance niraparib did not significantly improve progression-free survival or objective response rate compared with standard regimens[1][3][7]. Atezolizumab is developed and manufactured by Roche, and niraparib by GlaxoSmithKline. Key adverse effects are consistent with those of each agent, including immune-mediated reactions from atezolizumab and hematologic toxicities from niraparib[1][3].